Proton beam therapy aims to cut prostate cancer treatment time and side effects
NCT ID NCT01950351
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a shorter course of proton beam radiation (hypofractionated) in 241 men with early-stage prostate cancer that hasn't spread. The goal is to see if this precise radiation can kill cancer cells while causing fewer bowel and bladder side effects compared to standard radiation. Researchers are tracking side effects and quality of life over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proton beam radiation therapy
- What this could lead to
- If successful, this could offer a more precise, shorter course of radiation for prostate cancer with fewer bowel side effects.
- What could go wrong
- This is a mid-stage trial with 241 participants, so results are not yet definitive. There is still a risk of side effects, and the approach may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE ADENOCARCINOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.